Bli medlem
Bli medlem

Du är här


Hofseth Biocare ASA : Patent approval in Japan on Salmon Protein to alleviate anaemia

Hofseth BioCare ASA (HBC) is pleased to announce today the receipt of its Notice of Allowance from the Japanese Patent office for its patent application "Compositions and Methods for Increasing Iron Absorption" which uses its salmon protein hydrolysate to alleviate anaemia in humans suffering from low iron absorption.
Hofseth is now uniquely positioned to increased sales of its salmon protein hydrolysate powder using this biological efficacy with full IP protection in Japan and HBC anticipate similar allowances in other regions as well.

For more information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mob.: +47 93632966
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hofseth Biocare ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.